Literature DB >> 26131234

Association of interleukin-6 polymorphisms with susceptibility to hepatocellular carcinoma.

Xiaohuan Zheng1, Cuiping Han1, Rong Shan2, Haitao Zhang1, Zhaomin Zheng1, Yuanshui Liu1, Aiguang Wang1.   

Abstract

TARGET: Our study was to investigate the effects of interleukin-6 (IL-6) polymorphisms (rs2069837 and rs17147230) on the risk for hepatocellular carcinoma (HCC).
METHODS: A total of 226 HCC cases and 220 healthy controls were admitted into the study and genomic DNA was extracted from the peripheral blood. The genotyping was conducted by the method of polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Odds ratio (OR) and 95% confidence interval (CI) were used to evaluate the relationship of IL-6 rs2069837 and rs17147230 polymorphisms with HCC susceptibility.
RESULTS: The frequency of GG genotype of rs2069837 was higher in HCC patients, compared with controls (P < 0.05). Moreover, the results indicated that GG genotype was related with increased risk for HCC (OR = 2.303, 95% CI = 1.056-5.025). Similarly, the risk for G allele carriers was higher than that of A allele (OR = 1.392, 95% CI = 1.046-1.852). For rs17147230, TT genotype showed strong effect on HCC susceptibility (OR = 2.089, 95% CI = 1.135-3.845) and T allele appeared to be a risk factor for HCC (OR = 1.326, 95% CI = 1.010-1.740). Further analysis showed that G-T haplotype was associated with increased risk for HCC (OR = 3.125, 95% CI = 1.845-5.294, P = 0.000).
CONCLUSION: IL-6 rs2069837 as well as rs17147230 were associated with HCC susceptibility. In addition, G-T haplotype also served as a genetic-susceptibility factor for HCC.

Entities:  

Keywords:  Interleukin-6; hepatocellular carcinoma; polymorphisms

Year:  2015        PMID: 26131234      PMCID: PMC4483998     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  23 in total

1.  Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C.

Authors:  Annarosa Cussigh; Edmondo Falleti; Carlo Fabris; Davide Bitetto; Sara Cmet; Elisabetta Fontanini; Sara Bignulin; Ezio Fornasiere; Elisa Fumolo; Rosalba Minisini; Mario Pirisi; Pierluigi Toniutto
Journal:  Immunogenetics       Date:  2010-11-12       Impact factor: 2.846

2.  Gene polymorphism at the interleukin 6 -174 G > C locus affects the outcome of chronic hepatitis B.

Authors:  Carlo Fabris; Pierluigi Toniutto; Davide Bitetto; Giovanna Fattovich; Edmondo Falleti; Elisabetta Fontanini; Annarosa Cussigh; Rosalba Minisini; Giuseppa Occhino; Mario Pirisi
Journal:  J Infect       Date:  2009-06-18       Impact factor: 6.072

3.  Inhibition of rat liver fibrogenesis through noradrenergic antagonism.

Authors:  Liliane Dubuisson; Alexis Desmoulière; Boris Decourt; Laetitia Evadé; Christiane Bedin; Liliane Boussarie; Laurence Barrier; Michel Vidaud; Jean Rosenbaum
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

5.  Association of IFNAR2 and IL10RB genes in chronic hepatitis B virus infection.

Authors:  S Romporn; N Hirankarn; P Tangkijvanich; I Kimkong
Journal:  Tissue Antigens       Date:  2013-07

6.  The global health burden of infection-associated cancers in the year 2002.

Authors:  Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

7.  Hepatic stellate cells express the low affinity nerve growth factor receptor p75 and undergo apoptosis in response to nerve growth factor stimulation.

Authors:  N Trim; S Morgan; M Evans; R Issa; D Fine; S Afford; B Wilkins; J Iredale
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

Review 8.  Cytokines as mediators and targets for cancer cachexia.

Authors:  Josep M Argilés; Sílvia Busquets; Francisco J López-Soriano
Journal:  Cancer Treat Res       Date:  2006

9.  Interleukin-6-572C>G polymorphism-association with inflammatory variables in Korean men with coronary artery disease.

Authors:  Yangsoo Jang; Oh Yoen Kim; Yae Jung Hyun; Jey Sook Chae; Soo Jeong Koh; Yu Mi Heo; Donghoon Choi; Dong-Jik Shin; Kenneth Huttner; Jong Ho Lee
Journal:  Transl Res       Date:  2008-01-02       Impact factor: 7.012

Review 10.  Interleukin-6 and its receptor in cancer: implications for translational therapeutics.

Authors:  David S Hong; Laura S Angelo; Razelle Kurzrock
Journal:  Cancer       Date:  2007-11-01       Impact factor: 6.860

View more
  10 in total

1.  Polymorphisms in the 3'-UTR of SCD5 gene are associated with hepatocellular carcinoma in Korean population.

Authors:  Gyeong Im Yu; Kwang Ho Mun; Seon Hee Yang; Dong Hoon Shin; Jae Seok Hwang
Journal:  Mol Biol Rep       Date:  2018-08-30       Impact factor: 2.316

2.  Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.

Authors:  Satoshi Matsusaka; Diana L Hanna; Shu Cao; Wu Zhang; Dongyun Yang; Yan Ning; Yu Sunakawa; Satoshi Okazaki; Martin D Berger; Yuji Miyamato; Anish Parekh; Sebastian Stintzing; Fotios Loupakis; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2016-02-02       Impact factor: 12.531

3.  Association between interleukin-6 polymorphisms and urinary system cancer risk: evidence from a meta-analysis.

Authors:  Kaiping Zhang; Li Zhang; Jun Zhou; Zongyao Hao; Song Fan; Cheng Yang; Chaozhao Liang
Journal:  Onco Targets Ther       Date:  2016-01-27       Impact factor: 4.147

4.  Determination of IL-1B (rs16944) and IL-6 (rs1800796) genetic polymorphisms in IgA nephropathy in a northwest Chinese Han population.

Authors:  Daofa Zhang; Maowei Xie; Xiaohong Yang; Yin Zhang; Yan Su; Yanni Wang; Haiyang Huang; Hui Han; Wenning Li; Keying Fu; Huiluan Su; Wentan Xu; Yeguang Han; Ru Wang; Pei Zhang; Wei Wu; Yun Huang; Daojun Chen; Tianbo Jin; Jiali Wei
Journal:  Oncotarget       Date:  2017-05-04

5.  Multiple functional SNPs in differentially expressed genes modify risk and survival of non-small cell lung cancer in Chinese female non-smokers.

Authors:  Xue Fang; Zhihua Yin; Xuelian Li; Lingzi Xia; Xiaowei Quan; Yuxia Zhao; Baosen Zhou
Journal:  Oncotarget       Date:  2017-03-21

6.  Meta-analysis of the role of IL-6 rs1800795 polymorphism in the susceptibility to prostate cancer: Evidence based on 17 studies.

Authors:  Tong-Zu Liu; Zhong-Qiang Guo; Ting Wang; Yue Cao; Di Huang; Xing-Huan Wang
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

7.  Interleukin-6 gene polymorphisms and susceptibility to liver diseases: A meta-analysis.

Authors:  Xuehan Wang; Zhenghui Yan; Qingjian Ye
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

8.  Single nucleotide polymorphism of transforming growth factor-β1 and interleukin-6 as risk factors for ovarian cancer.

Authors:  Amira Ben Ahmed; Sabrina Zidi; Wassim Almawi; Ezzeddine Ghazouani; Amel Mezlini; Besma Yacoubi Loueslati; Mouna Stayoussef
Journal:  Cent Eur J Immunol       Date:  2020-11-01       Impact factor: 2.085

9.  Association between interleukin 6 polymorphisms (rs1800796, rs1800795, rs2069837, rs17147230, and rs1800797) and hepatocellular carcinoma susceptibility: a meta-analysis.

Authors:  Omid Emami Aleagha; Pembe Oltulu; Masoud Sadeghi
Journal:  Clin Exp Hepatol       Date:  2020-12-30

10.  Interleukin-6 polymorphisms in HCC patients chronically infected with HCV.

Authors:  Faisal Adnan; Najeeb Ullah Khan; Aqib Iqbal; Ijaz Ali; Arnolfo Petruzziello; Rocco Sabatino; Annunziata Guzzo; Giovanna Loquercio; Gerardo Botti; Sanaullah Khan; Muhammad Naeem; Muhammad Ismail Khan
Journal:  Infect Agent Cancer       Date:  2020-04-01       Impact factor: 2.965

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.